SAINTE-FOY, QUEBEC--(Marketwire - August 12, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announces that upon the signing of the employment contract of Olivier Meyer as President and Chief Executive Officer effective July 16, 2008, the Corporation's Board of Directors granted him 150,000 stock options at a price of $0.11 per option and expiring July 15, 2013.
